Inflammatory bowel disorders: Gene therapy solutions

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 5, 2003, Pages 495-502

  Wirtz, Stefan ^a   Neurath, Markus F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Animal models; Crohn's disease; Gene transfer; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6 RECEPTOR; NATALIZUMAB; RECOMBINANT INTERLEUKIN 10; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; GENE THERAPY; GENE TRANSFER; HUMAN; INFECTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN TARGETING; REVIEW; VIRAL GENE DELIVERY SYSTEM;

CYTOKINES; GASTROINTESTINAL TRACT; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INFLAMMATORY BOWEL DISEASES; STEM CELLS;

ANIMALIA;

EID: 0142154210     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med (2002) 347(6):417-429.
2. Wirtz S, Neurath MF: Animal models of intestinal inflammation: New insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int J Colorectal Dis (2000) 15(3):144-160.
3. Blumberg RS, Strober W: Prospects for research in inflammatory bowel disease. J Am Med Assoc (2001) 285(5):643-647.
4. Strober W, Fuss IJ, Nakamura K, Kitani A: Recent advances in the understanding of the induction and regulation of mucosal inflammation. J Gastroenterol (2003) 38(Suppl 15):S55-S58.
5. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V et al: Association of nod2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 411(6837):599-603.
6. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP et al: A frameshift mutation in nod2 associated with susceptibility to Crohn's disease. Nature (2001) 411(6837):603-606.
7. Farrell RJ, Peppercorn MA: Ulcerative colitis. Lancet (2002) 359(9303):331-340.
8. Fiocchi C: Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology (1998) 115(1):182-205.
9. Elson CO: Commensal bacteria as targets in Crohn's disease. Gastroenterology (2000) 119(1):254-257.
10. Neurath MF, Finotto S, Glimcher LH: The role of Th1/Th2 polarization in mucosal immunity. Nat Med (2002) 8(6):567-573.
11. Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F: Control of intestinal inflammation by regulatory T cells. Immunol Rev (2001) 182:190-200.
12. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem (2003) 278(11):8869-8872.
13. Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel disease. Gastroenterology (2002) 122(6):1592-1608.
14. Ganesan S, Travis SP, Ahmad T, Jazrawi R: Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 3(9):1301-1306.
15. Blam ME, Stein RB, Lichtenstein GR: Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives. Am J Gastroenterol (2001) 96(7):1977-1997.
16. Helbling D, Breitbach TH, Krause M: Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol (2002) 14(12):1393-1395.
17. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121(5):1088-1094.
18. Plevy SE: Corticosteroid-sparing treatments in patients with Crohn's disease. Am J Gastroenterol (2002) 97(7):1607-1617.
19. Lorenz HM, Kalden JR: Perspectives for TNF-α-targeting therapies. Arthritis Res (2002) 4(Suppl 3):S17-S24.
20. Bauditz J, Wedel S, Lochs H: Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 50(2):196-200.
21. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn's disease. N Engl J Med (2003) 348(1):24-32.
22. Van Assche G, Rutgeerts P: Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis (2002) 8(4):291-300.
23. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 182(5):1281-1290.
24. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol (2003) 98(2):369-376.
25. Ito H: Anti-interleukin-6 therapy for Crohn's disease. Curr Pharm Des (2003) 9(4):295-305.
26. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med (1996) 2(9):998-1004.
27. Hibi T, Inoue N, Ogata H, Naganuma M: Introduction and overview: Recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol (2003) 38(Suppl 15):S36-S42.
28. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K et al: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461-1472.
29. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49(1):42-46.
30. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, Koningsberger JC et al: Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytolkine interferon γ. Gut (2002) 50(2):191-195.
31. Sandberg JW, Lau C, Jacomino M, Finegold M, Henning SJ: Improving access to intestinal stem cells as a step toward intestinal gene transfer. Hum Gene Ther (1994) 5(3):323-329.
32. Pickles RJ, Fahrner JA, Petrella JM, Boucher RC, Bergelson JM: Retargeting the coxsackie virus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol (2000) 74(13):6050-6057.
33. Wirtz S, Galle PR, Neurath MF: Efficient gone delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut (1999) 44(6):800-807.
34. Lozier JN, Yankaskas JR, Ramsey WJ, Chen L, Berschneider H, Morgan RA: Gut epithelial cells as targets for gene therapy of hemophilia. Hum Gene Ther (1997) 8(12):1481-1490.
35. Li M, Lonial H, Citarella R, Lindh D, Colina L, Kramer R: Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther (1996) 3(4):221-229.
36. Westbrook CA, Chmura SJ, Arenas RB, Kim SY, Otto G: Human APC gene expression in rodent colonic epithelium in vivo using liposomal gene delivery. Hum Mol Genet (1994) 3(11):2005-2010.
37. Schmid RM, Weidenbach H, Draenert GF, Lerch MM, Liptay S, Schorr J, Beckh KH, Adler G: Liposome mediated in vivo gene transfer into different tissues of the gastrointestinal tract. Z Gastroenterol (1994) 32(12):665-670.
38. Katsel PL, O'Connell B, Mizuno TM, Mobbs CV, Greenstein RJ: Liposome mediated gene transfer into GH3 cells, and rat brain, liver and gut: Comparison of different polar or aliphatic domains. Int J Surg Investig (2000) 1(5):415-429.
39. Cheng DY, Kolls JK, Lei D, Noel RA: In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Hum Gene Ther (1997) 8(6):755-764.
40. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G: The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther (1995) 2(2):107-115.
41. Croyle MA, Walter E, Janich S, Roessler BJ, Amidon GL: Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 9(4):561-573.
42. Foreman PK, Wainwright MJ, Alicke B, Kovesdi I, Wickham TJ, Smith JG, Meier-Davis S, Fix JA, Daddona P, Gardner P, Huang MT: Adenovirus-mediated transduction of intestinal cells in vivo. Hum Gene Ther (1998) 9(9):1313-1321.
43. Ferrari S, Kitson C, Farley R, Steel R, Marriott C, Parkins DA, Scarpa M, Wainwright B, Evans MJ, Colledge WH, Geddes DM et al: Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther (2001) 8(18):1380-1386.
44. Chen Y, Song K, Eck SL: An intra-Peyer's patch gene transfer model for studying mucosal tolerance: Distinct roles of B7 and IL-12 in mucosal T cell tolerance. J Immunol (2000) 165(6):3145-3153.
45. Nemerow GR: Cell receptors involved in adenovirus entry. Virology (2000) 274(1):1-4.
46. Leon RP, Hedlund T, Meech SJ, Li S, Schaack J, Hunger SP, Duke RC, DeGregori J: Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA (1998) 95(22):13159-13164.
47. Wickham TJ, Tzeng E, Shears LL 2nd, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A, Kovesdi I: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 71(11):8221-8229.
48. Ye X, Jerebtsova M, Ray PE: Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther (2000) 11(4):621-627.
49. Takehara T, Hayashi N, Yamamoto M, Miyamoto Y, Fusamoto H, Kamada T: In vivo gene transfer and expression in rat stomach by submucosal injection of plasmid DNA. Hum Gene Ther (1996) 7(5):589-593.
50. Wright JF, Qu G, Tang C, Sommer JM: Recombinant adeno-associated virus: Formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Dev (2003) 6(2):174-178.
51. During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P: Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med (1998) 4(10):1131-1135.
52. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, Poulsen D, Leone P, Xu R, Dicker BL, Lipski J et al: An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science (2000) 287(5457):1453-1460.
53. Brittan M, Wright NA: Gastrointestinal stem cells. J Pathol (2002) 197(4):492-509.
54. Nicklin SA, Baker AH: Tropism-modified adenoviral and adeno-asociated viral vectors for gene therapy. Curr Gene Ther (2002) 2(3):273-293.
55. Berns KI, Hauswirth WW: Adeno-associated viruses. Adv Virus Res (1979) 25:407-449.
56. Brown GR, Thiele DL, Silva M, Beutler B: Adenoviral vectors given intravenously to immunocompromised mice yield stable transduction of the colonic epithelium. Gastroenterology (1997) 112(5):1586-1594.
57. Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol (2002) 20:495-549.
58. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K et al: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature (1995) 378(6552):88-91.
59. Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF Jr, Foley E, Moskaluk CA, Bickston SJ, Cominelli F: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells. J Immunol (1999) 162(11):6829-6835.
60. Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F: Bioactive IL-18 expression is upregulated in Crohn's disease. J Immunol (1999) 163(1):143-147.
61. Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T: Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology (2000) 119(6):1514-1523.
62. Gracie JA, Robertson SE, McInnes IB: Interleukin-18. J Leukocyte Biol (2003) 73(2):213-224.
63. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, Park CS, Hamaoka T, Ohta T, Kurimoto M, Fujiwara H: Synergy of IL-12 and IL-18 for IFN-γ gene expression: IL-12-induced STAT4 contributes to IFN-γ promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol (2002) 168(3):1146-1153.
64. Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer-zum Buchenfelde KH, Neurath MF: IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-γ promoter in primary CD4+ T lymphocytes. J Immunol (1998) 160(8):3642-3647.
65. Dinarello CA: Interleukin-18. Methods (1999) 19(1):121-132.
66. Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF: Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol (2002) 168(1):411-420.
67. Kanai T, Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, Ishii H, Totsuka T, Iiyama R, Okamoto R, Ikeda M et al: Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology (2001) 121(4):875-888.
68. Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, Drillenburg P, van Deventer SJ, Chvatchko Y, Te Velde AA: Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-α production in mice. Gastroenterology (2001) 121(6):1372-1379.
69. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S, Eigler A: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am J Physiol Regul Integr Comp Physiol (2001) 281(4):R1264-R1273.
70. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D et al: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med (2000) 6(5):583-588.
71. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136(7):2348-2357.
72. Hogaboam CM, Vallance BA, Kumar A, Addison CL, Graham FL, Gauldie J, Collins SM: Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest (1997) 100(11):2766-2776.
73. Fort M, Lesley R, Davidson N, Menon S, Brombacher F, Leach M, Rennick D: IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol (2001) 166(4):2793-2800.
74. Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P: Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther (2000) 11(12):1731-1741.
75. Lalani I, Bhol K, Ahmed AR: Interleukin-10: Biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol (1997) 79(6):469-483.
76. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Immunity (1994) 1(7):553-562.
77. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75(2):263-274.
78. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med (1999) 190(7):995-1004.
79. Tomoyose M, Mitsuyama K, Ishida H, Toyonaga A, Tanikawa K: Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand J Gastroenterol (1998) 33(4):435-440.
80. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM: Interleukin 10 gene transfer prevents experimental colitis in rats. Gut (2000) 46(3):344-349.
81. Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, Te Velde A, Rodriguez Pena MS: IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther (2002) 9(24):1715-1721.
82. Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM: The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol (2001) 166(12):7625-7633.
83. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ: Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut (2003) 52(7):981-987.
84. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289(5483):1352-1355.
85. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E: Biological containment of genetically modified Lactococcus lactis for Intestinal delivery of human interleukin 10. Nat Biotechnol (2003) 21(7):785-789.
86. Van Montfrans C, Hooijberg E, Rodriguez Pena MS, De Jong EC, Spits H, Te Velde AA, Van Deventer SJ: Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology (2002) 123(6):1877-1888.
87. Van Montfrans C, Rodriguez Pena MS, Pronk I, Ten Kate FJ, Te Velde AA, Van Deventer SJ: Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology (2002) 123(6):1865-1876.
88. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-β. Annu Rev Immunol (1998) 16:137-161.
89. Giladi E, Raz E, Karmeli F, Okon E, Rachmilewitz D: Transforming growth factor-β gene therapy ameliorates experimental colitis in rats. Eur J Gastroenterol Hepatol (1995) 7(4):341-347.
90. Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W: Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation. J Exp Med (2000) 192(1):41-52.
91. Babyatsky MW, Rossiter G, Podolsky DK: Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology (1996) 110(4):975-984.
92. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S et al: Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype, for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA (1999) 96(22):12816-12821.